| Brian D Masonholder, DO | |
|
109 E Walnut St, Columbus Junction, IA 52738-1014 | |
| (319) 728-2429 | |
| (319) 728-7600 |
| Full Name | Brian D Masonholder |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 109 E Walnut St, Columbus Junction, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851333942 | NPI | - | NPPES |
| 080128957 | Other | IA | RAILROAD MEDICARE |
| 0171975 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 01809 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Brian D Masonholder, DO Po Box 2027, Iowa City, IA 52244-2027 Ph: (319) 339-3855 | Brian D Masonholder, DO 109 E Walnut St, Columbus Junction, IA 52738-1014 Ph: (319) 728-2429 |
News Archive
Rates of new anal cancer diagnoses and deaths related to human papillomavirus, the most common sexually transmitted infection, have increased dramatically over the last 15 years, according to researchers at The University of Texas Health Science Center at Houston.
To build on a groundbreaking study that used brain imaging to identify individuals with suicidal thoughts, Carnegie Mellon University's Marcel Just and the University of Pittsburgh's David A. Brent have received a five-year, $3.8 million grant from the National Institute for Mental Health.
A Bluetooth heart monitor could text your local hospital if you are about to have a heart attack, according to research published today in Inderscience's International Journal of Electronic Healthcare.
The standard of care for acute concussion may undergo a dramatic change, depending on the results of a new exercise treatment that physicians at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo have developed and begun testing. It is the first randomized, controlled clinical trial of this exercise treatment for concussion.
AcroMetrix, a leading manufacturer of quality control material for clinical diagnostic and blood testing laboratories, announced today the launch of its OptiQual HPV Genotype Panel. Designed to help clinical laboratories comply with CLIA guidelines for qualitative molecular assays that detect Human Papillomavirus (HPV), this addition to AcroMetrix's line of women's health products can assist laboratorians with the validation and verification of their molecular HPV tests.
› Verified 9 days ago